Study on TAC-001 for Patients with Advanced or Metastatic Solid Tumors
Sponsor: Tallac Therapeutics
Sponsor score: 0
ClinicalTrials ID:NCT05399654
This clinical trial is testing the safety and effectiveness of a new drug, TAC-001, in patients with advanced or metastatic solid tumors. The study will also look at how the drug moves through the body.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The INCLINE-101 study is a Phase 1/2 clinical trial that aims to evaluate the safety and initial effectiveness of TAC-001, a new drug given through an IV, in patients with advanced or metastatic solid tumors. Researchers will also study how the drug is processed in the body.
Eligibility Criteria
Inclusion Criteria
- Have a confirmed diagnosis of a solid tumor based on lab tests.
- Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
- Have adequate organ function as determined by specific medical tests.
Exclusion Criteria
- Have a history of or currently have another type of cancer besides the one being treated in this study.
- Have known cancer that has spread to the brain or the area around the brain.
- Have an allergy to the study drug or similar medications.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of Southern California (USC) | 90033 | Los Angeles | California |
| University of Colorado | 80045 | Aurora | Colorado |
| Sarah Cannon Research Institute (SCRI)- Denver | 80218 | Denver | Colorado |
| AdventHealth Cancer Institute | 32804 | Orlando | Florida |
| Sarah Cannon Research Institute (SCRI)- Florida Cancer Specialists and Research Institute, LLC | 32827 | Orlando | Florida |
| John Theurer Cancer Center | 07601 | Hackensack | New Jersey |
| Weill Cornell Medicine- NYU Clinical Cancer Center | 10065 | New York | New York |
| West Cancer Center & Research Institute | 38138 | Germantown | Tennessee |
| The University of Texas MD Anderson Cancer Center | 77030 | Houston | Texas |
| NEXT Oncology | 75039 | Irving | Texas |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.